DEF 14A: Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders, Outlines Key Proposals

Biofrontera Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on the election of directors and ratification of the company's auditor.

Summary

• Biofrontera Inc. is holding its 2024 Annual Meeting of Stockholders on June 12, 2024, at 10:00 a.m. Eastern Time, in a virtual-only format.
• Stockholders of record as of April 15, 2024, are entitled to vote at the meeting.
• The meeting will address the election of two Class III directors to serve until the 2027 annual meeting and the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR the election of John J. Borer III, J.D. and Prof. Hermann Luebbert, Ph.D. as Class III directors, and FOR the ratification of Marcum LLP.
• As of the record date, there were 5,089,413 shares of Common Stock and 4,806 shares of Series B-1 Convertible Preferred Stock outstanding, representing 5,089,413 and 28,191 votes respectively.
• Proxy materials were made available to stockholders on or about May 3, 2024.
• Stockholders can vote by internet, telephone, or mail, or virtually during the meeting.
• A quorum requires at least one-third of the outstanding shares entitled to vote to be present in person or by proxy.
• The company will announce preliminary voting results at the meeting and publish final results in a Form 8-K filing within four business days.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the agenda for the annual meeting. The tone is neutral and professional, with no major positive or negative surprises. The change in auditor and the material weakness in internal control are negative points, but the overall sentiment is stable.

Positives

• The company is using a virtual-only format for the annual meeting, which can expedite delivery to stockholders through a lower-cost, more environmentally responsible method.
• The Board of Directors is recommending qualified candidates for election as Class III directors.
• The Audit Committee has recommended the ratification of Marcum LLP as the independent registered public accounting firm.
• The company provides multiple methods for stockholders to vote, including internet, telephone, and mail.

Negatives

• Grant Thornton LLP resigned as the company's independent registered public accounting firm effective May 30, 2023.
• There was a material weakness in internal control over financial reporting reported by the Company related to management's review of work performed by specialists as of December 31, 2021.

Risks

• The classification of the Board of Directors may have the effect of delaying or preventing changes in control of the company.
• Failure to achieve applicable Annual Minimum Sales (as defined in the Second A&R Ameluz LSA) is a termination event in certain circumstances, unless waived by Biofrontera Pharma and Biofrontera Bioscience.
• The company faces risks relating to its financial condition, development and commercialization activities, operations, strategic direction and intellectual property, as more fully discussed under Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and our other filings with the SEC.

Future Outlook

The company has agreed to appoint up to two additional directors to its Board of Directors, each of whom shall be designated by Rosalind Advisors, Inc.

Management Comments

• Prof. Luebbert's experience with the Company's business and industry, as well as his ability to effectively identify strategic priorities of the Company and facilitate execution of the Company's strategy, makes combining the roles of Chairman and Chief Executive Officer the best leadership structure for the Company at this time.

Industry Context

The document does not explicitly discuss broader industry trends, but the company's focus on dermatology and its reliance on licensing agreements are common in the pharmaceutical and biotech industries.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the company's reliance on licensing agreements is a common practice in the pharmaceutical industry, similar to companies like Ligand Pharmaceuticals or Royalty Pharma, which focus on acquiring and managing royalty streams from drug sales.
• The virtual-only format for the annual meeting is becoming increasingly common, especially among smaller companies looking to reduce costs.

Management Changes

Corporate Governance

Related Party Transactions

• The company has significant related party transactions with Biofrontera AG and its subsidiaries, including the Ameluz License and Supply Agreement and service agreements.
• Purchases of licensed products from Biofrontera Pharma were $23.4 million and $17.9 million for the years ended December 31, 2023 and 2022, respectively.
• Expenses related to the Services Agreement were $0.2 million and $0.7 million for the years ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• The outcome of the votes on the election of directors and ratification of the auditor will impact shareholders.
• The company's performance and financial stability affect employees, customers, and suppliers.

Next Steps

• Stockholders are encouraged to vote on the proposals before the meeting.
• The company will hold the Annual Meeting on June 12, 2024.
• The company will file a Form 8-K with the final voting results.

Key Dates

Keywords

proxy statement, annual meeting, directors, auditor, Marcum LLP, Biofrontera